WILD 20

a breakdown product of G(M1) ganglioside; has antiplatelet effect & prolonged bleeding time without interfering with the coagulative or fibrinolytic processes

Also Known As:

WILD-20; WILD20; beta-D-Glucopyranoside, 2--amino-3-hydroxy-4-eicosenyl O-beta-D-galactopyranosyl-(1-3)-O-2-amino-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-(alpha-neuraminosyl-(2-3))-O-beta-D-galactopyranosyl-(1-4)-, (R-(R*,S*-(E)))-

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/01/1993 - "A new, orally active de-N-acetylated lysoglycosphingolipid (WILD20) was evaluated as antiinflammatory agent using a model of chemically-induced inflammatory bowel disease (IBD) in the rat to mimic human ulcerative colitis and Chron's disease. "
2.	Neoplasms (Cancer) 12/29/1995 - "When peritumorally administered, WILD20 impaired tumour growth and potentiated the peritumoral effects of recombinant interleukin 2. The results obtained merit exploration of the therapeutical possibilities of this agent in human cancer patients."
3.	Inflammation (Inflammations) 10/01/1994 - "A new water-soluble, orally absorbable de-N-acetyl-lysoganglioside (WILD20), breakdown product of the monosialoganglioside GM1, was found to influence some parameters of neutrophil response to inflammation stimuli. "
4.	Ulcerative Colitis 12/01/1993 - "A new, orally active de-N-acetylated lysoglycosphingolipid (WILD20) was evaluated as antiinflammatory agent using a model of chemically-induced inflammatory bowel disease (IBD) in the rat to mimic human ulcerative colitis and Chron's disease. "

Related Drugs and Biologics

1.	Interleukin-2 (IL2)
2.	Anti-Inflammatory Agents (Anti-Inflammatories)